rs8832 — IL4R IL4R 3'UTR Asthma Exacerbation Variant

3' untranslated region variant in the IL-4 receptor alpha chain gene; the G allele is associated with elevated type-2 inflammatory endotype in asthma and predicts exacerbation risk and pharmacogenetic response to IL-4 pathway blockade

See your personal result for IL4R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL4R rs8832 — A 3'UTR Tag for Type-2 Asthma Exacerbation Risk

Interleukin-4 (IL-4) is the master switch for Th2 immune polarization — the immune phenotype that underlies asthma, atopic dermatitis, and allergic rhinitis. Its receptor, encoded by IL4R at chromosome 16p12.111 IL4R at chromosome 16p12.1
The IL4R gene spans approximately 30 kb on chromosome 16 and encodes the alpha chain of the IL-4 receptor (IL-4Rα), a shared signaling subunit for both IL-4 and IL-13 receptor complexes, amplifies or moderates the Th2 signal depending on which alleles a person carries. The rs8832 variant sits in the 3' untranslated region (3'UTR) of IL4R — downstream of the protein-coding sequence — in a region that regulates mRNA stability, translation efficiency, and post-transcriptional expression control.

The G allele at rs8832 is the more common allele in European, South Asian, and Latino populations (~56–58%) but is substantially less common in African populations (~23%), reflecting strong population differentiation at this locus. As a 3'UTR variant, rs8832 does not change the IL-4Rα protein sequence; instead, it tags a haplotype affecting IL4R expression regulation, and may itself affect microRNA binding sites or RNA-binding protein recognition sequences in the 3'UTR.

The Mechanism

3'UTR variants influence gene expression by altering binding sites for microRNAs (miRNAs)22 microRNAs (miRNAs)
small non-coding RNA molecules that bind to the 3'UTR of target mRNAs and repress translation or promote mRNA degradation — a key layer of post-transcriptional gene regulation or RNA-binding proteins that stabilize or destabilize mRNA transcripts. A variant in the 3'UTR of IL4R that impairs miRNA-mediated repression would increase IL-4Rα protein levels or prolong receptor activity, amplifying downstream Th2 signaling through the JAK1/TYK2–STAT6 pathway. Elevated IL-4Rα density increases cellular responsiveness to IL-4 and IL-13, promoting IgE class switching in B cells, mucus production, airway smooth muscle hyperreactivity, and eosinophil recruitment — the hallmarks of type-2 inflammation in allergic asthma.

The rs8832 G allele also tags a broader haplotype pattern at the IL4R locus, meaning its functional effect may reflect linkage disequilibrium with other functional IL4R variants rather than a direct 3'UTR mechanism. This distinction matters for interpreting association data but not for the practical consequence: the G allele reliably identifies individuals with elevated type-2 inflammatory activity when present in a homozygous state.

The Evidence

The strongest evidence for rs8832 comes from a multicenter Japanese observational study33 multicenter Japanese observational study
Sunadome et al. 2017: 217 asthma patients followed for 2 years across multiple respiratory medicine centers; 60 patients experienced exacerbations; type-2 endotype defined by serum periostin ≥95 ng/mL in which the GG genotype emerged as a significant risk marker for asthma exacerbations specifically within the type-2 inflammatory endotype subgroup. Among the 27 patients with type-2 endotype and exacerbations, GG genotype carried an odds ratio of 4.01 (95% CI 1.47–11.0; p=0.007). Critically, this association was absent in the overall asthma population — it was only visible when patients were stratified by inflammatory endotype first. This endotype-restricted pattern is consistent with rs8832 operating through IL-4Rα-mediated Th2 amplification specifically, not through general airway disease mechanisms.

Pharmacogenetic evidence comes from a phase II randomized controlled trial44 phase II randomized controlled trial
Slager et al. 2012: 407 non-Hispanic white subjects randomized to pitrakinra (IL-4/IL-13 antagonist) at 1 mg, 3 mg, or 10 mg versus placebo; pharmacogenetic analysis examined IL4R haplotype effects on treatment response. Subjects homozygous for the G allele at rs8832 who received pitrakinra had significantly fewer exacerbations and fewer nocturnal awakenings than GG subjects on placebo, with a statistically significant dose-response relationship (p=0.009). This indicates the G allele tags individuals who benefit most from blocking the IL-4/IL-13 pathway — the precise mechanism targeted by dupilumab, the first approved biologic for atopic disease.

Epigenetic interaction data from the Isle of Wight birth cohort55 Isle of Wight birth cohort
Zhang et al. 2014: population-based cohort established 1989; asthma status examined at ages 10 and 18; DNA methylation at IL4R CpG site cg26937798 measured longitudinally showed that among GG carriers, higher methylation at cg26937798 within the IL4R locus was associated with lower asthma risk at age 18 (p=0.01). This suggests the biological effect of the G allele is partially modifiable by epigenetic factors — an observation consistent with the known role of 3'UTR variants in influencing epigenetic-regulatory crosstalk.

Practical Actions

For individuals carrying GG at rs8832 who have asthma, the key clinical implication is endotype clarification. The rs8832 GG genotype specifically tags type-2 inflammation, which is the subtype most responsive to biologic therapies targeting the IL-4/IL-13 pathway. Serum periostin, blood eosinophil count, and exhaled nitric oxide (FeNO) are the clinical markers that confirm type-2 endotype and inform treatment selection. Carriers who have confirmed type-2 asthma are the most appropriate candidates for dupilumab or other IL-4Rα–targeted biologics.

Interactions

rs8832 is in the IL4R gene alongside several coding variants with established functional effects. The rs1801275 (Q576R) missense variant changes the IL-4Rα intracellular signaling domain and has its own independent effect on Th2 amplification. When both rs8832 G and rs1801275 G are present, the combined effect on IL-4Rα function and asthma risk may be additive — one variant affecting receptor expression regulation and one affecting signaling domain activity. The rs2070874 T allele in the IL4 promoter (a ligand-side variant) further compounds Th2 amplification when co-present with receptor-side variants.

Proposed compound action for supervisor: rs8832 GG with rs1801275 AG/GG — combined receptor-expression and receptor-signaling gain-of-function at the same locus. Both G alleles at these two positions indicate maximal IL-4Rα pathway amplification; combined recommendation should emphasize type-2 endotype biomarker testing and proactive discussion of IL-4Rα biologic candidacy, with monitoring of serum periostin, blood eosinophils, and FeNO to confirm endotype and timing for dupilumab initiation.

Genotype Interpretations

What each possible genotype means for this variant.

AA Low-Risk Genotype Normal

Common protective allele — lower type-2 asthma exacerbation risk

You carry two copies of the A allele at rs8832 in the IL4R 3' untranslated region. This genotype is associated with lower risk of type-2 inflammatory endotype in asthma and does not predict the exacerbation pattern or biologic responsiveness seen in GG carriers. About 23% of people of European ancestry and 59% of people of African ancestry share this genotype. If you have asthma, your inflammatory phenotype is less likely to be driven by IL-4Rα overactivity at this locus.

AG Intermediate Risk Intermediate

One G allele — moderately elevated type-2 asthma exacerbation susceptibility

The additive inheritance pattern at rs8832 means each G allele incrementally shifts IL-4Rα expression regulation toward higher type-2 signaling capacity. As a heterozygote, you have one 3'UTR allele that may reduce post-transcriptional repression of IL4R and one that does not. Whether this translates to clinically meaningful differences from the AA genotype depends on your broader immune genetics (IL4 promoter variants, IL13 coding variants, STAT6 variants) and environmental exposures. The pharmacogenetic data suggest AG individuals sit between the AA low-responders and GG high-responders to IL-4 pathway blockade.

GG Elevated Risk Genotype High Risk

GG genotype — elevated type-2 asthma exacerbation risk and heightened biologic response prediction

The association between rs8832 GG and type-2 asthma exacerbation is endotype-restricted: the risk is specifically elevated in patients with confirmed type-2 inflammation (high periostin, elevated eosinophils, elevated IgE). This is not simply a higher rate of asthma, but a higher rate of severe exacerbations within the type-2 subgroup — the mechanistically relevant context where IL-4Rα amplification matters most.

The pharmacogenetic evidence from the pitrakinra RCT is clinically translatable: the IL-4 receptor alpha subunit targeted by pitrakinra is the same subunit (IL-4Rα) targeted by dupilumab, the FDA-approved biologic for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. GG carriers who have confirmed type-2 endotype are the patients most likely to have their IL-4Rα-driven inflammation controlled by dupilumab.

The epigenetic interaction from the Isle of Wight cohort (Zhang et al. 2014) adds a modifiable layer: among GG carriers, higher methylation at cg26937798 within IL4R was protective against asthma at age 18. This suggests that lifestyle and environmental factors that favorably regulate IL4R methylation — including avoiding cigarette smoke exposure, allergen reduction, and early immune education through diverse microbial exposures — may partially offset the genetic susceptibility.